Theravance Biopharma, Inc.
TBPHDrugs in Pipeline
9
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
TBPH Earnings Report
EPS Est: $0.14 | FQ end 2026-06
How TBPH's past catalysts played out
ampreloxetine
Symptomatic Neurogenic Orthostatic Hypotension
TD-1792
Staphylococcal Skin Infection
Velusetrag
Gastroparesis
TD-0903
Acute Lung Injury (ALI) Associated With COVID-19
TD-8236
Asthma
TD-9855 Group 1
Fibromyalgia
velusetrag dose 1
Gastroparesis
TD-9855
Neurogenic Orthostatic Hypotension
400 microgrammes GSK961081
Pulmonary Disease, Chronic Obstructive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ampreloxetine | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension | - | - |
TD-1792 | Phase 2 | Staphylococcal Skin Infection | - | - |
Velusetrag | Phase 2 | Gastroparesis | - | - |
TD-0903 | Phase 2 | Acute Lung Injury (ALI) Associated With COVID-19 | - | - |
TD-8236 | Phase 2 | Asthma | - | - |
TD-9855 Group 1 | Phase 2 | Fibromyalgia | - | - |
velusetrag dose 1 | Phase 2 | Gastroparesis | - | - |
TD-9855 | Phase 2 | Neurogenic Orthostatic Hypotension | - | - |
400 microgrammes GSK961081 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Theravance Biopharma, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Theravance Biopharma, Inc.'s (TBPH) pipeline across Phase 3, Phase 2. Its lead program is ampreloxetine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Theravance Biopharma, Inc.'s next FDA catalyst?→
Theravance Biopharma, Inc.'s (TBPH) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TBPH biotech catalysts?→
Add TBPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Theravance Biopharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.